Value of serum fibroblast growth factor 21 levels in assessing disease status in patients with liver cancer
Objective To investigate the application value of serum fibroblast growth factor 21(FGF21)levels in assessing disease status in patients with liver cancer.Methods A cross-sectional study was conducted involving 157 hospitalized patients who received treatment at the Department of Infectious Disease,The First Hospital of Jiaxing between July 2020 and August 2021(54 patients with liver cancer and 103 patients with chronic liver disease).General patient data were collected,and serum FGF21 levels were measured using the enzyme-linked immunosorbent assay.Pearson correlation analysis was performed to investigate the correlation between FGF21 levels and various indicators.Logistic regression analysis was performed to identify risk factors associated with the severity of liver cancer.Receiver operating characteristic curve analysis was conducted to evaluate the predictive value of FGF21 levels for liver cancer.Results Serum FGF21 levels differed significantly between the liver cancer and chronic liver disease groups[399.91(293.05,572.65)ng/L vs.174.16(105.39,255.16)ng/L,Z=7.32,P<0.001).Pearson correlation analysis indicated that FGF21 levels were positively correlated with sex,age,smoking,alcohol consumption,fasting blood glucose,total bilirubin,and prothrombin time(all P<0.05).Logistic regression analysis revealed that FGF21 is an independent risk factor for liver cancer(OR=1.102,P<0.001).According to the receiver operating characteristic curve,the area under the curve for FGF21 levels was 0.856,with an optimal cutoff value of 274.99 ng/L.This cutoff value demonstrated a sensitivity of 0.833 and a specificity of 0.796 for predicting liver cancer.Conclusion In patients with liver cancer,elevated levels of FGF21 can be observed even when fasting blood glucose is normal,indicating its potential as a predictor for the occurrence of liver cancer.Furthermore,increased FGF21 levels are an independent risk factor for the development of liver cancer.